# Updates in Hematology & Hematologic Malignancies

### Friday, April 11, 2025 8am-4pm

The Omni Charlottesville Hotel, 212 Ridge McIntire Road Charlottesville, VA

Provided by the University of Virginia School of Medicine and the School of Nursing



### Agenda

### 7:00-8:00

Registration, Breakfast and Exhibits

8:00-8:05

Welcome/Program Overview Hillary Maitland, MD, MS

#### 8:05–9:25 Lymphoid Malignancy

8:05-8:30 Lymphoid Malignancy

Nathan Roberts, MD 8:30-9:15

How I treat CLL in 2025 Matthew Davids, MD, MMSc

9:15-9:25 **Questions** Panel

9:30- 10:00 Break/Exhibits

\_\_\_\_\_

#### 10:00-11:25 Classical Heme

10:00-10:25 **Classical Heme** Valery Kogler, MD

#### 10:25-11:10 Treatment of Concomitant Arterial and Venous Thrombosis

Stephan Moll, MD

11:10-11:25 **Questions** 

Panel 11:30-11:55

**Clinical trials** Alana Ferrari, PharmD Cameron Lee, PharmD

11:55-12:40 Lunch/Exhibits

#### 12:40 PM-2:25 Acute Leukemia

12:40 -1:05 **Updates in Acute Myeloid Leukemia** Michael Keng, MD

#### 1:05-1:30

Advances in Frontline Management of B-cell Acute Lymphoblastic Leukemia

Firas El Chaer, MD, MSHCM

#### 1:30-2:15

#### **Clonal hematopoiesis of indeterminate potential (CHIP): Origins and clinical implications** David Steensma, MD

2:15-2:25 **Questions** Panel

T UNCI

#### 2:25-3:45 Plasma Cell

#### 2:25-3:10

Advances in Multiple Myeloma and Other Plasma Cell Disorders in 2025 Carlyn Tan, MD

3:10-3:35 **Pulmonary Complications of Stem Cell Transplant** Jeffrey Sturek, MD, PhD

3:35-3:45 **Questions** Panel

3:45-3:50 Conference Summary/ Evaluations Firas El Chaer, MD

### **Program Overview**

This program will explore research and advances in the diagnosis and management of benign hematologic conditions and hematologic malignancies, including indications for novel therapies. Case-based presentations will highlight recommendations for treatment of common hematologic diagnoses.

### **Educational Outcomes**

- Define the new Acute Myeloid Leukemia (AML) classifications and discuss updated guidelines.
- Discuss the new treatment modalities for Myelodysplastic Syndromes (MDS).
- Explain the pathogenesis of Clonal Hematopoiesis of Indeterminate Potential (CHIP), identify its clinical implications and associated risks, and discuss current management strategies and future research directions.
- Describe current practices and innovations in transfusion medicine.
- Identify diagnostic and therapeutic strategies in multiple myeloma.
- Analyze pulmonary complications in hematologic diseases.
- Examine current and emerging therapies in lymphoma treatment.
- Discuss treatment strategies for concomitant arterial and venous thrombosis.

### **Target Audience**

Community hematologists and oncologists, as well as advanced practice providers, nurses, and pharmacists are welcome to attend.



### **Course Directors**

#### Firas El Chaer, MD

Associate Professor of Medicine; Medical Director of Chronic & Acute Leukemia, MDS & MPN Clinical Research Team

Hillary Maitland, MD, MS Associate Professor of Medicine

### **Invited Guest Faculty**



Matthew Davids, MD, MMSc Director of Clinical Research, Dana-Farber Cancer Institute



**Stephan Moll, MD** Professor of Medicine, Division of Hematology, University of North Carolina School of Medicine



David P. Steensma, MD, FACP Chief Medical Officer Ajax Therapeutics, Cambridge MA



**Carlyn Tan, MD** Assistant Attending Memorial Sloan Kettering Cancer Center

### **UVA Faculty**

\* Indicates Planning Committee

Rachel Chai, PA\* Physician Assistant, Infusion Center

**Gina DeGenarro, DNP, RN, CNS, AOCN\*** Associate Professor of Nursing

Alana Ferrari, PharmD, BCOP\* Clinical Pharmacist, Hematology/ Oncology

Caroline Jones, PharmD\* Pharmacist, Clinical Services

Michael Keng, MD Associate Professor of Medicine Valery Kogler, MD

Associate Medical Director of Cytotherapy & Cellular Apheresis, Transfusion Medicine / Blood Bank Services, Department of Pathology & Laboratory Medicine

**Cameron R. Lee, PharmD** Pharmacist, Investigational Drug Services

Nathan Roberts, MD Assistant Professor of Medicine

Krithika Shanmugasundaram, MD\*

Assistant Professor of Medicine

Jeffrey M. Sturek, MD, PhD Assistant Professor, Pulmonary & Critical Care

## Tanya Thomas, DNP, APRN, AGCNS-BC, OCN\*

Clinical Nurse Specialist; Oncology and Hazardous Medication Safety

### **Registration and Fees**

Registration and payment are available at the **UVA Continuing Medical Education portal**. Registration will close midnight on Monday April 1, 2025. NO WALK IN REGISTRATION.

Syllabus will be available online the week of the conference until 30 days after the program. \*See cancellation policy prior to registration.

	Early Bird Discount (before 2/18/25)	After 2/18/25
Physicians	\$150	\$200
Other Healthcare Professionals	\$50	\$75

Please Note:Policies on cancellation, payment methods and accommodation requests can be found on our website under FAQs. Additional questions, please contact **uvacme@virginia.edu** or 434-924-5310.

### Accreditation

In support of improving patient care, UVA Health Continuing Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the



Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

UVA Health Continuing Education designates this live activity for a maximum of **6.00 AMA PRA Category 1 Credits**<sup>M</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

UVA Health Continuing Education awards up to **6.00 contact hour(s)** for nurses who participate in this educational activity and complete the post activity evaluation.

UVA Health Continuing Education awards 6.00 hours of participation to a participant who successfully completes this educational activity. UVA Health Continuing Education maintains a record of participation for six (6) years.

Credit will be uploaded to CPE Monitor within 60 days of the end date of the activity. A certificate from our learning portal validates only learner participation. It will be the responsibility of the pharmacist or pharmacy technician to provide the correct information in order to receive credit for participating in this CE activity. Please log into your NABP Profile to see your credit recorded and print your official transcript.

UVA Health Continuing Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria.



This activity is designated for **6.00 AAPA Category 1 CME credits**. PAs should only claim credit commensurate with the extent of their participation. The University of Virginia School of Medicine and School of Nursing has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria.

This activity is designated for **6.00 AAPA Category 1 Self-Assessment CME credits**. PAs should only claim credit commensurate with the extent of their participation.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to **6.00 MOC points** in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

### **Contact Information**

#### Kara Watts

CE Program Manager, Office of Continuing Medical Education

#### kt7r@uvahealth.org

434-409-0754